Longboard Pharmaceuticals — Investor Day (October 2023)
49 slides from Longboard Pharmaceuticals's investor day presentation, Oct 11, 2023
Slide 1: Investor & Analyst Event October 11, 2023
Slides from a presentation titled “Investor & Analyst Event October 11, 2023 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our vision; commercial opportunities and analogs; our development approach and position to have best-in-class d
Slide 3: Longboard Participants and Featured Guest Speakers
Longboard Participants Featured Guest Speakers Kevin Lind President and CEO / Director Randall Kaye MD EVP, Chief Medical Officer Dennis Dlugos MD, MSCE Professor of Neurology & Pediatrics at Children’s Hospital of Philadelphia (CHOP) and University of Pennsylvania School of Medicine; Director of th
Slide 4: Longboard Introduction
Longboard Introduction Kevin Lind, President & CEO
Slide 5: Our Vision is Backed by 20+ Years of World Class GPCR Research
Our Vision is Backed by 20+ Years of World Class GPCR Research Longboard Thesis Vision A world where devastating neurological conditions are no longer devastating 5 Longboard Pharmaceuticals Differentiated & innovative clinical approaches Relevant M&A analogs JAZZ - GW $7.2B PFE - ARNA $6.7B UCB - Z
Slide 6: Longboard's Best-in-Class Product Candidates
Longboard’s Best-in-Class Product Candidates * Through the Royalty Purchase Agreement Definitions: DEEs=developmental and epileptic encephalopathies; S1P = sphingosine 1-phosphate; PK=pharmacokinetics; PD=pharmacodynamics; EEG = electroencephalogram We hold rights to other product candidates, includ
Slide 7: Key Messages for LP352
Key Messages for LP352 Tremendous unmet need exists in the treatment of DEEs - both for the 4 DEEs with recently approved novel therapeutics and the broader DEE population 1 Polytherapy continues to be SOC for DEE patients and a safer, efficacious, less burdensome (no echocardiograms) 5HT2C will be
Slide 8: Impact of Developmental and Epileptic Encephalopathies (DEEs)
DEEs commonly begin in infancy or childhood and are associated with frequent seizures of multiple different types, intellectual disability, and significant delay or regression. Decision-Making Tree for Therapeutics Impact of Developmental and Epileptic Encephalopathies (DEEs) No Yes Safety Burden Ef
Slide 9: Prevalence of Other DEEs Could Exceed the Approved 4
The prevalence of all "Other DEEs" could exceed the total of the “Approved 4” combined 4 DEE Syndromes Have Approved Therapies; 20+ Have None Sources: Dravet Syndrome Foundation, LGS Foundation Definitions: LGS = Lennox-Gastaut Syndrome, CDD = CDKL5 Deficiency Disorder, TSC = Tuberous Sclerosis Comp
Slide 10: LP352 First-in-Class 5-HT2C Superagonist
LP352 First-in-Class 5-HT2C Superagonist with Next-Generation Selectivity, Being Dose-Optimized to Treat a Broad Range of DEEs Effectively and Safely Randall E. Kaye, MD Chief Medical Officer
Slide 11: Brain Regions Involved in Multiple Types of Seizures
LGS = Lennox Gastaut syndrome; DS = Dravet syndrome; SUDEP = sudden unexpected death in epilepsy Source: Lindquist et. al. 2023; Burke et. al. 2014; Bosco et. al. 2023; Created with BioRender.com Brain Regions Involved in Multiple Types of Seizures Dysfunction of the circuits involving the cortex (i
Slide 12: 5-HT2C Receptors are Expressed in Seizure-Related Brain Regions
Source: (1) The Human Protein Atlas; (2) NeuroSeq; (3) Massey et. al. 2021; (4) Simonsson et. al. 2022; (5) Blond et. al. 2023 5-HT2C Receptors are Expressed in Seizure-Related Brain Regions 5-HT2C receptor expression is restricted to the brain 5-HT2C receptors are highly expressed in the brainstem,
Slide 13: Role of 5-HT2C Receptors in Epilepsy
Sources: Gharedaghi MH et al., Exp Brain Res. 2014; Bagdy G et al., J Neurochemistry. 2007; Strac DS et al., Front Neurosci. 2016; Sourbron J et al., ACS Chem Neuroscience. 2016; Tecott LH et al, Nature. 1995; Upton N et al, Eur J Pharmacol. 1998; Orban G et al., CNS Neurosci Ther. 2014; Schoonjans
Slide 14: 5-HT2 Evolution in Rare Epilepsies
5-HT2 Evolution in Rare Epilepsies *R=undisclosed Designed & Being Dose-Optimized for DEEs Weight Loss Drug Repurposed for Dravet Compound FINTEPLA® (fenfluramine, ZX008) LP352 History Designed to be a next-generation selective 5-HT2C superagonist Dose optimization for DEEs BID formulation work ongo
Slide 15: LP352 Designed to be a Next-Generation 5-HT2C with Greater Selectivity
LP352 Designed to be a Next-Generation 5-HT2C with Greater Selectivity and Specificity 1 Third party study previously commissioned by Arena, 2 BELVIQ FDA approved prescribing information 06/2012; Note: The above table is for illustrative purposes only and is not a head-to-head comparison. Difference
Slide 16: Avoiding Drug-Drug Interactions in Polypharmacy
Cerny (2016) Drug Metabolism and Disposition 44:1246 *From Longboard HCP Survey 2023 Given the common nature of complex polypharmacy in patients with DEEs, avoiding DDIs is of particular importance Many ASMs are affected by CYP enzyme inhibitors, notably CYP2D6 (fenfluramine, carbamazepine), CYP3A4
Slide 17: The Potential of LP352
* Based on first two cohorts The Potential of LP352 Reduced seizure activity in model of neuronal hyperexcitability in zebrafish Reduced epileptiform activity in fish and rodent models of disinhibition Reduced duration and number of epileptiform events in zebrafish model of Dravet Syndrome In genera
Slide 18: LP352 Inhibited Seizure Activity in Multiple Preclinical Models
LP352 Inhibited Seizure Activity in Multiple Preclinical Models Definitions: ASM = anti-seizure medication; MOA = mechanism of action Corneal Kindling Pentylenetetrazol (PTZ) (i.v.) Scn1aA1783V/WT Transgene scn1lab Transgene Ethyl ketopentenoate (EKP) Kainic acid (KA) Model Partial (focal) limbic se
Slide 19: LP352 102: Ph 1 PK/PD CNS Study in Adult Healthy Volunteers
LP352 102: Ph 1 PK/PD CNS Study in Adult Healthy Volunteers Topline data 28 Days Screening Period Day 25 Follow-up Up-Titration Days 1-2 Maintenance* Days 3-11 (target treatment Taper Down Day 11 (start taper after AM dose) Additional Cohorts Ongoing Cohort 1 (n=10) 6 mg TID Cohort 2 (n=10) 12 mg TI
Slide 20: Steady State Plasma & CSF Concentrations for LP352
Steady State Plasma & CSF Concentrations for LP352 (6mg & 12mg) *Topline data Ki Ki 12 mg TID Exceeded Ki Value for 5-HT2C Activity throughout Dosing Interval* LP352 selectivity may limit off-target effects associated with currently available non-selective ASMs
Slide 21: PACIFIC Study Update
PACIFIC Study Update LONGBOARD
Slide 22: LP352 Ph 1b/2a PACIFIC Study in Patients with DEEs
6 mg 9 mg 12 mg Participant remains on 6, 9 or 12 mg based on tolerability during up-titration 5 Wks Screening Period 30 Days Follow-up Period Randomization & Up-Titration Days 1-15 Maintenance* Days 16-75 Down- Titration Days 76- 80/90** LP352 Ph 1b/2a PACIFIC study in patients with DEEs * Maintena
Slide 23: Study Objectives
Primary: To investigate the safety, tolerability, and efficacy of multiple doses of LP352 in adolescent and adult participants with DEE Secondary To characterize the pharmacokinetics (PK) of LP352 in adolescent and adult participants with DEE To characterize the pharmacodynamic (PD) effects of LP352
Slide 24: Diagnostic Eligibility Criteria: Dravet, LGS and Other DEEs
Diagnostic Eligibility Criteria: Dravet Syndrome, Lennox-Gastaut Syndrome and Other DEEs *Abnormal inter-ictal EEG background activity with inter-ictal slow spike-and-wave pattern ≤2.5 Hz or inter-ictal generalized paroxysmal fast activity. All patients: Treatment-resistant countable motor seizures
Slide 25: Seizure Reduction for Approved Drugs in DEEs
1. Lagae, et al The Lancet 2019; 2. Knupp, et al JAMA Neurology 2022; 3. Knight,et al, The Lancet Neurology 2022; 4. Epidiolex HCP website Dravet & LGS & TSC Seizure Reduction for Approved Drugs in DEEs FEN 0.2mg/kg FEN 0.7mg/kg Ganaxolone Cannabidiol 10mg/kg Cannabidiol 20mg/kg Cannabid
Slide 26: PACIFIC Study Enrollment Summary
PACIFIC Study Enrollment Summary 52 Participants randomized Diagnosis* Vast majority of eligible participants who complete PACIFIC expected to enter Open-Label Extension 100% have entered to date** 42 US 10 AUS Adult/Pediatric participants Range: 12-55 Mean: 24.2 / Median: 23.0 40 Adult (18+) 12 Ped
Slide 27: Key Areas of Focus in PACIFIC Topline Readout
Key Areas of Focus in PACIFIC Topline Readout Seizure Reduction Clinically meaningful seizure reductions across the DEE landscape and consistent with approved treatments Safety Favorable safety & tolerability in line with previous Longboard studies to date OLE Participation Vast majority of eligible
Slide 28: Commercial Opportunity for LP352
Commercial Opportunity for LP352 Kevin Lind
Slide 29: Quantitative and Qualitative HCP and Caregiver Research
Quantitative HCP Research 100 Physicians Objective: Validating Unmet Needs And LP352 Potential Criteria: Board Certified HCPs specializing in Neurology or Epileptology Treat at least 20 patients with DEEs in the past 12 months Familiar with Fintepla and Epidiolex Note: Most participants have some cl
Slide 30: Commercial Opportunity for Approved 4 DEE Indications
Commercial Opportunity for “Approved 4” DEE Indications Kevin Lind
Slide 31: DEE Types Treated in the Past 12 Months
DEE Types Treated in the Past 12 Months Total Respondents DEE Type Treated in Past 12 Months Total Respondents Nearly All HCPs Treat Patients with the “Approved 4” Longboard and third-party market research analysis
Slide 32: DEE Indications Represent a $6B Total US + EU Market Opportunity
1) Longboard and third-party research 2022 – projections for 2040 for US + EU4/UK, 2) UCB Annual Report 2022, 3) Jazz Pharmaceuticals Annual Report 2022, 4) UCB press release dated January 9, 2023, 5) Jazz Corporate Overview August 2023 DEE Indications Represent a $6B Total US + EU Market Opportunit
Slide 33: HCPs Report a Need for More Effective and Safer Anti-Seizure Medications
HCPs Report a Need for More Effective and Safer Anti-Seizure Medications % Frustrated with Lack of Available New Treatment Options for DEE Type Among those who treat any patients with DEE type Mean # of Seizures Per Week Mean # of ASMs Per Patient Dravet 12 3.4 LGS 19 3.5 TSC 6 3.0 CDD 13 2.9 % Rate
Slide 34: Influence on ASM Decisions
Influence on ASM Decisions When allocating 100 points across factors If I see a patient with epilepsy and give them enough valium, they’ll be seizure free, but then they'll be sleeping all day. That’s not quality of life. So, we must find the cocktail that gives them the best seizure control with th
Slide 35: Fintepla Performance on Most Important Criteria
The clinical trial in Dravet was amazing, really impressive efficacy. I would say Fintepla is comparable to other medications in reality. Now these are very difficult patients so it makes sense, but most people would say Fintepla is not as robust in its efficacy.” – Epileptologist, Primarily Pediatr
Slide 36: Top Reasons Why Unlikely to Prescribe Fintepla
Top Reasons Why Unlikely to Prescribe Fintepla* Mean % Caregivers Decline Fintepla Despite HCP Recommendation *Among those who don’t currently or are unlikely to prescribe Fintepla Fintepla Safety & Burden are Hard to Overcome; Caregivers Also Decline Somewhat Regularly 25% I think of Fintepla as a
Slide 37: Reality of the Treatment Paradigm: Safety, Efficacy and Burden
Reality of the Treatment Paradigm: Balancing of Safety, Efficacy and Burden Polytherapy Approach: DEE patients are highly refractory and on an average of 3.5 medications simultaneously The combination of these criteria impact utilization AND FINTEPLA is re-assessed every six months No Yes Safety Bur
Slide 38: Multiple Potential Ways to Win
Multiple Potential “Ways to Win” Capture market share in “Approved 4” with best-in-class profile (safety, efficacy, burden)
Slide 39: Top Reasons for Prescribing LP352 Over Fintepla
Top Reasons for Prescribing LP352 Sampled Product Profile Over Fintepla* HCPs Prefer LP352* Over Fintepla and Are More Likely to Prescribe it Because of the Superior Safety Profile *Those who would prescribe LP352 sampled product profile over Fintepla HCPs prefer LP352* mainly because of the superio
Slide 40: Multiple Potential Ways to Win
Multiple Potential “Ways to Win” Capture market share in “Approved 4” with best-in-class profile (safety, efficacy, burden) Broaden market in “Approved 4” DEE’s with preferred safety and burden profile $6B Total Addressable Market
Slide 41: Commercial Opportunity for Broad DEE Indication
Commercial Opportunity for Broad DEE Indication Kevin Lind
Slide 42: Nearly All HCPs Treat Patients with All DEE Diagnoses
Nearly All HCPs Treat Patients with All DEE Diagnoses; Collectively, the Number of “Other DEEs” is Significant DEE Types Treated in the Past 12 Months Percent of Patients with DEE Type
Slide 43: Unmet Needs for Patients with Other DEEs
Unmet Needs for Patients with Other DEEs Among those who treat patients with other DEEs (not “Approved 4”) HCPs Report a Need for More Effective and Safer Anti-Seizure Medications for Other DEEs Mean # of Seizures Per Week Mean # of ASMs Per Patient Dravet 12 3.4 LGS 19 3.5 TSC 6 3.0 CDD 13 2.9 Othe
Slide 44: Unmet Need for New ASM Approved for Broad Range of DEE Types
Unmet Need for New ASM Approved to Treat a Broad Range of DEE Types Caregivers Report Challenges Accessing Newer ASMs – A Tremendous Unmet Need for Broad Indication Remains 83% Believe there is a significant unmet need 7- Significant unmet need 6- 4- 3- 1- No unmet need 5-(0% selected) 2-(0% selec
Slide 45: HCPs Prefer LP352 with a Broad DEE Indication
HCPs Prefer LP352 with a Broad DEE Indication, and Anticipate This Will Positively Impact DEE Patients’ Treatment Options 6-Very strong preference for broad DEE indication 5- 4- 3- 2- 1-Very strong preference of indication specific to Dravet, LGS, TSC, CDD 7-Significant positive impact 6- 5- 4-No im
Slide 46: Caregivers React Positively to Broad LP352 Profile
7- Strongly agree 6- 5- 4- Neither agree nor disagree 2- 1- Strongly disagree Nearly All Caregivers React Positively to Broad LP352 Profile and Would Ask Their HCP About It; LP352 Gives Hope of a Better Life 83% Agree that LP352 gives them hope that their child could have a better life 3- (0% select
Slide 47: Multiple Potential Ways to Win: $6B Total Addressable Market
Multiple Potential “Ways to Win” $6B Total Addressable Market Capture market share in “Approved 4” with best-in-class profile (safety, efficacy, burden) Broaden market in “Approved 4” DEE’s with preferred safety and burden profile Expand market to address significant unmet need across “Other DEE” pa
Slide 48: Key Messages for LP352
Key Messages for LP352 Tremendous unmet need exists in the treatment of DEEs - both for the 4 DEEs with recently approved novel therapeutics and the broader DEE population 1 Polytherapy continues to be SOC for DEE patients and a safer, efficacious, less burdensome (no echocardiograms) 5HT2C will be
Slide 49: Q&A: LBPH Investor & Analyst Event 2023
Q&A LBPH Investor & Analyst Event 2023 Thank you to our attendees! [email protected]
Longboard Pharmaceuticals — Investor Day (October 2023) on 6ix